ClinicalTrials.gg
RecruitingNCT04046796DISCO-TWINUpdated Mar 30, 2025

Genetic Causes of Discrepant Clinic in Monogenic Twins

An observational study in Rare Diseases and Genetic Predisposition to Disease, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by University Hospital Tuebingen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Sex
All
01

Study summary

In the DISCO-TWIN study (prospective, open-label molecular-genetic study), twin pairs with one healthy and one affected twin with molecularly undiagnosed diseases will be analysed by means of omics technologies and/ or re-analysed using existing datasets. Phenotype and omics data will be shared within the University Hospital Tübingen and with external collaborators to improve the diagnostic rate of the subjects included in the study.

02

Conditions studied

  • Rare Diseases
  • Genetic Predisposition to Disease

Keywords

  • Rare Diseases
  • Genetic Predisposition
  • Omics Technology
  • Next Generation Sequencing (NGS)
03

In context

Rare Diseases

592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.

This study's planned enrollment of 50 is below the median of 133 across 208 observational studies indexed under Rare Diseases.

Browse Rare Diseases studies →

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Twin pair monozygotic clinically (phenotypic) discordant twins

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Twin pair monozygotic clinically (phenotypic) discordant twins
  • Unclear diagnosis
  • Suspected (mono-)genetic cause of the disease in one twin

Exclusion criteria

Exclusion Criteria:

  • Missing of both twin/ legal representative
  • No distinct phenotype
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Healthy twin

    Genetic: NGS Diagnostic

  • Effected Twin

    Twin with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location.

    Genetic: NGS Diagnostic

Interventions

  • GeneticNGS Diagnostic

    Blood take for genetic diagnostic.

    Also known as: Omics Technology

06

What researchers measure

Primary outcomes

  1. Number of new Candidate Genes

    Number of new Candidate Genes for complex or serious diseases through a comparative genetic analysis of monozygotic clinically discordant twins

    Time frame: Day 1

Secondary outcomes

  1. Number of putative disease causes

    Number characterizations of the identified putative disease causes.

    Time frame: Day 1

  2. Number of diagnosis

    Number of patients receiving appropriate therapy after successful diagnosis

    Time frame: Day 1

  3. Number of molecular causes of diagnostically unclear rare diseases

    Number of molecular causes of diagnostically unclear rare diseases

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Dec 2025, 72 months after the start.

Of 88 observational studies under Rare Diseases, half reached primary completion within 118 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 183. This study's planned 72 months is below that.

Rare Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2019
First posted
Aug 6, 2019
StartActual
Dec 1, 2019
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2027
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04046796
Responsible party
Sponsor
First posted
Aug 6, 2019
Start date
Dec 1, 2019
Primary completion
Dec 2025 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 30, 2025

Study contacts

Jeannette Hübener-Schmid, Dr.
Contact
jeannette.huebener@med.uni-tuebingen.de
+49 7071 29 ext. 72276
Andreas Dufke, PD Dr.
Contact
andreas.dufke@med.uni-tuebingen.de
+49 7071 29 ext. 86413
Jeannette Hübener-Schmid, Dr.
principal investigator · University Hospital Tübingen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion